Volume 72, Issue 5, Pages (November 2017)

Slides:

Advertisements

Similar presentations

Volume 45, Issue 5, Pages (May 2004)

Advertisements

Urologist Practice Affiliation and Intensity-modulated Radiation Therapy for Prostate Cancer in the Elderly Brent K. Hollenbeck, Samuel R. Kaufman, Phyllis.

Volume 59, Issue 2, Pages (February 2011)

Volume 51, Issue 2, Pages (February 2007)

Oncol Res Treat 2016;39: DOI: /

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Maurizio Brausi, Federica Rizzi, Saverio Bettuzzi European Urology

Volume 47, Issue 4, Pages (April 2005)

Testosterone Therapy in Men With Prostate Cancer

Volume 61, Issue 6, Pages (June 2012)

Volume 70, Issue 6, Pages (December 2016)

Prostate Cancer: Highlights from 2006

Claude C. Schulman, Jacques Irani, Juan Morote, Jack A

Volume 60, Issue 5, Pages (November 2011)

Volume 60, Issue 5, Pages (November 2011)

Volume 53, Issue 5, Pages (May 2008)

Volume 69, Issue 1, Pages (January 2016)

Hormone Therapy for Prostate Cancer: Exploring Current Controversies

Prostate Cancer Epidemic in Sight?

Volume 52, Issue 4, Pages (October 2007)

Volume 62, Issue 6, Pages (December 2012)

Volume 63, Issue 1, Pages (January 2013)

Volume 59, Issue 2, Pages (February 2011)

Volume 66, Issue 2, Pages (August 2014)

Volume 68, Issue 5, Pages (November 2015)

Volume 67, Issue 2, Pages (February 2015)

What is New in Hormone Therapy for Prostate Cancer in 2007?

Volume 61, Issue 4, Pages (April 2012)

Volume 53, Issue 4, Pages (April 2008)

Volume 67, Issue 3, Pages (March 2015)

Volume 67, Issue 6, Pages (June 2015)

Volume 71, Issue 5, Pages (May 2017)

Laurent Boccon-Gibod European Urology Supplements

Volume 64, Issue 6, Pages (December 2013)

Prostate Cancer Epidemic in Sight?

Volume 53, Issue 2, Pages (February 2008)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 61, Issue 6, Pages (June 2012)

Volume 53, Issue 6, Pages (June 2008)

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Volume 66, Issue 2, Pages (August 2014)

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 50, Issue 5, Pages (November 2006)

Anna Grenabo Bergdahl, Erik Holmberg, Sue Moss, Jonas Hugosson

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 55, Issue 3, Pages (March 2009)

Volume 72, Issue 4, Pages (October 2017)

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base Amy C. Moreno,

Volume 71, Issue 5, Pages (May 2017)

Jacques Irani European Urology Supplements

Volume 53, Issue 1, Pages (January 2008)

Volume 49, Issue 4, Pages (April 2006)

Volume 68, Issue 1, Pages (July 2015)

Maurizio Brausi, Federica Rizzi, Saverio Bettuzzi European Urology

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Long-Term Hormonal Therapy: Who Would Benefit?

Volume 59, Issue 4, Pages (April 2011)

Gender differences in treatment outcomes of tuberculosis patients in Taiwan: a prospective observational study J.-Y. Feng, S.-F. Huang, W.-Y. Ting, Y.-C.

Volume 74, Issue 6, Pages (December 2018)

Axel Heidenreich European Urology Supplements

Volume 53, Issue 6, Pages (June 2008)

Management of Prostate Cancer: Global Strategies

Differences in patterns of care and outcomes between grade II and grade III molecularly defined 1p19q co-deleted gliomas Debra Nana Yeboa, James B. Yu,

Volume 51, Issue 2, Pages (February 2007)

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Axel Heidenreich European Urology Supplements

Volume 54, Issue 1, Pages (July 2008)

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

Volume 72, Issue 5, Pages 738-744 (November 2017) Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer Skyler B. Johnson, Nataniel H. Lester-Coll, Jacqueline R. Kelly, Benjamin H. Kann, James B. Yu, Sameer K. Nath European Urology Volume 72, Issue 5, Pages 738-744 (November 2017) DOI: 10.1016/j.eururo.2017.06.020 Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 1 Proportion of patients treated with androgen suppression and external-beam radiation with low-dose rate brachytherapy (LDR-B) boost between 2004 and 2012 relative to dose-escalated external beam radiation therapy alone. European Urology 2017 72, 738-744DOI: (10.1016/j.eururo.2017.06.020) Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 2 (A) Unadjusted and (B) propensity-matched Kaplan-Meier survival curves by either dose-escalated external beam radiation therapy (DE-EBRT) or low-dose-rate brachytherapy (LDR-B) boost. European Urology 2017 72, 738-744DOI: (10.1016/j.eururo.2017.06.020) Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 3 Kaplan-Meier survival curves for men aged <60 yr with no comorbidities and stratified by treatment type with either dose-escalated external beam radiation therapy (DE-EBRT) or low-dose-rate brachytherapy (LDR-B) boost (7-yr overall survival 85% vs 90%; p<0.001). European Urology 2017 72, 738-744DOI: (10.1016/j.eururo.2017.06.020) Copyright © 2017 European Association of Urology Terms and Conditions